| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S81320-1mg买3赠1 |
99.80% | ￥184.00 |
>10 | - | - | - | - |
|
S81320-2mg买3赠1 |
99.80% | ￥280.00 |
>10 | - | - | - | - |
|
S81320-5mg买3赠1 |
99.80% | ￥395.00 |
>10 | - | - | - | - |
|
S81320-10mg买3赠1 |
99.80% | ￥650.00 |
>10 | - | - | - | - |
|
S81320-50mg买3赠1 |
99.80% | ￥1980.00 |
>10 | - | - | - | - |
|
S81320-100mg买3赠1 |
99.80% | ￥3100.00 |
>10 | - | - | - | - |
|
| 产品描述： | Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL)[1] |
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | IC50: 3 nM (BTK in CD69 B cell);BTK | ||||||||||||||||||||
| 体内研究： | Acalabrutinib (100 mg twice per day) assessed for thrombus formation at injured arterioles of the mice, exhibits more selective for inhibiting BTK and has virtually no inhibition of platelet activity | ||||||||||||||||||||
| 参考文献： | 1. Wu J, et al. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016 Mar 9;9:21 2. Herman SE, et al. The Bruton's tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2016 Nov 30 | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
